| Drug General Information |
| Drug ID |
D0IU2F
|
| Former ID |
DNC001581
|
| Drug Name |
NMED-160
|
| Indication |
Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89]
|
Discontinued in Phase 2 |
[1]
|
|---|
| Therapeutic Class |
Analgesics
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Voltage-dependent N-type calcium channel |
Target Info |
Modulator |
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Calcium signaling pathway
|
|
Synaptic vesicle cycle
|
|
Retrograde endocannabinoid signaling
|
|
Cholinergic synapse
|
|
Serotonergic synapse
|
|
GABAergic synapse
|
|
Dopaminergic synapse
|
|
Taste transduction
|
|
Type II diabetes mellitus
|
|
Morphine addiction
|
|
Nicotine addiction
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Ionotropic glutamate receptor pathway
|
|
Metabotropic glutamate receptor group III pathway
|
|
Metabotropic glutamate receptor group II pathway
|
|
Thyrotropin-releasing hormone receptor signaling pathway
|
|
Endogenous cannabinoid signaling
|
|
GABA-B receptor II signaling
|
|
Reactome
|
Depolarization of the Presynaptic Terminal Triggers the Opening of Calcium Channels
|
|
WikiPathways
|
Calcium Regulation in the Cardiac Cell
|
|
Synaptic Vesicle Pathway
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016715) |
|---|
